Applied DNA Schedules Fiscal 2019 Third Quarter Financial Results Conference Call for Tuesday, August 13, 2019 at 4:30 PM ET
August 06 2019 - 5:00AM
Business Wire
Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today it
plans to release financial results for its fiscal 2019 third
quarter ended June 30, 2019 after market close on Tuesday, August
13, 2019. In conjunction with the release, the Company has
scheduled a conference call at 4:30 p.m. Eastern Time that will
also be broadcast live over the Internet.
What:
Applied DNA’s Fiscal 2019 Third Quarter
Financial Results Conference Call
When:
Tuesday, August 13, 2019, at 4:30 p.m.
Eastern Time
Where:
Via phone by dialing +1 844-887-9402 or +1
412-317-6798 and ask to join the Applied DNA call; via webcast.
A telephonic replay of the conference call will be available for
one day and may be accessed by calling +1 877-344-7529 or +1
412-317-0088 with the passcode 10133063. The webcast will be
archived within the ‘Events and Presentations’ portion of the
‘Investors’ page to the company’s website.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping and pre-clinical nucleic acid-based
therapeutic drug candidates.
Applied DNA makes life real and safe by providing innovative,
molecular-based technology solutions and services that can help
protect products, brands, entire supply chains, and intellectual
property of companies, governments and consumers from theft,
counterfeiting, fraud and diversion.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
Common stock listed on NASDAQ under the symbol ‘APDN’ and
warrants are listed under the symbol ‘APDNW’.
Forward Looking Statements
The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of the Private
Securities Litigation Act of 1995. Forward-looking statements
describe Applied DNA’s future plans, projections, strategies and
expectations, and are based on assumptions and involve a number of
risks and uncertainties, many of which are beyond the control of
Applied DNA. Actual results could differ materially from those
projected due to its ability to repay the Notes if not converted,
history of net losses, limited financial resources, limited market
acceptance, ability to maintain its NASDAQ listing and various
other factors detailed from time to time in Applied DNA’s SEC
reports and filings, including our Annual Report on Form 10-K filed
on December 18, 2018 and our subsequent quarterly reports on Form
10-Q filed on February 7, 2019 and May 9, 2019, and other reports
we file with the SEC, which are available at www.sec.gov. Applied
DNA undertakes no obligation to update publicly any forward-looking
statements to reflect new information, events or circumstances
after the date hereof to reflect the occurrence of unanticipated
events, unless otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190806005279/en/
Investors: Sanjay M. Hurry, LHA Investor Relations,
212-838-3777, shurry@lhai.com Web: www.adnas.com
Twitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024